Rwanda has initiated the world’s first clinical trial for the treatment of Marburg virus disease, the World Health Organization (WHO) announced on Tuesday, October 15.
The trial, described as a “groundbreaking effort,” is being conducted in partnership with the WHO and aims to test the safety and efficacy of two treatments: Remdesivir, an antiviral used for COVID-19, and MBP091, a specialized antibody designed specifically to combat Marburg virus disease, according to WHO Regional Director for Africa Dr. Matshidiso Moeti.
This health initiative is part of a broader effort that began two years ago when the WHO identified 17 African countries, including Rwanda, as willing to conduct clinical trials. Currently, there are no approved treatments or vaccines for Marburg virus disease.
Rwanda declared a Marburg virus outbreak on September 27.
On Wednesday, October 16, Dr. Moeti visited response sites in Kigali, where she commended Rwandan health workers and survivors for their dedication and bravery. She arrived in Rwanda on Tuesday to observe the ongoing response efforts and the WHO’s collaboration with the government.
Earlier this month, Rwanda also launched a vaccination campaign, with over 700 individuals at high risk already vaccinated, according to the Ministry of Health. On October 12, the Sabin Vaccine Institute, a U.S.-based organization, delivered approximately 1,000 additional doses of its investigational single-dose Marburg vaccine to support the outbreak response.
